Introduced on March 20, 2013 Public Law Pub.L. 113–14 | Number of Co-Sponsors 0 | |
 | ||
Full title To amend the Federal Food, Drug, and Cosmetic Act to reauthorize user fee programs relating to new animal drugs and generic new animal drugs. Sponsored by Senator Tom Harkin (D-Iowa) | ||
The Animal Drug and Animal Generic Drug User Fee Reauthorization Act of 2013 (S
Contents
The bill was signed by President Barack Obama on June 13, 2013, becoming Pub.L. 113–14.
Provisions/Elements of the bill
This summary is based largely on the summary provided by the Congressional Budget Office, a public domain source.The Animal Drug and Animal Generic Drug User Fee Reauthorization Act of 2013 would authorize the collection and spending of fees by the Food and Drug Administration (FDA) for certain activities to expedite the development and marketing approval of drugs for use in animals. Fees would supplement appropriated funds to cover FDA’s costs associated with reviewing certain applications and investigational submissions for brand and generic animal drugs. Such fees could be collected and made available for obligation only to the extent and in the amounts provided in advance in appropriation acts. The legislation would extend through fiscal year 2018, and make several technical changes to, FDA’s existing fee programs for brand and generic animal drugs, which expire at the end of fiscal year 2013.
Senate
The Animal Drug and Animal Generic Drug User Fee Reauthorization Act of 2013 (S
House
The Animal Drug and Animal Generic Drug User Fee Reauthorization Act of 2013 was received in the United States House of Representatives on May 9, 2013. It passed the House on June 3, 2013 by a vote of 390-12, recorded in Roll Call Vote 185.